Loading stock data…
ATNM
$1.13+0.02 (+1.80%)
Market ClosedLast close May 1
Actinium Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Actinium Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.13. The stock is currently near its 52-week low of $0.95, remaining 19.3% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why ATNM maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.13
Potential Upside
5%
Whystock Fair Value$1.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus5 analysts
Buy
Mean target$5.00+342.5%
Range$2.00 – $9.00
Fundamentals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, A...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$41.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-387.80%
Volume
Today's trading volume
145,496
Recent News
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Actinium: Q3 Earnings Snapshot
NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Friday reported a loss of $5.1 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 16 cents.
Sector Update: Health Care Stocks Advance Monday Afternoon
Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select